Emerging anti-inflammatory drugs for atherosclerosis

Keyphrases

• Anti-inflammatory Drugs 100%
• Inflammation 66%
• Cardiovascular Disease 66%
• Statins 66%
• Methotrexate 66%
• Pathway Inhibitors 66%
• Cardiovascular Mortality 33%
• Most Common Cause 33%
• Anti-inflammatory Effect 33%
• Chemokine (C-C motif) Ligand 2 (CCL2) 33%
• Expert Opinion 33%
• Inflammatory Pathways 33%
• Patient Experience 33%
• Recurrent Events 33%
• Phase III Clinical Trial 33%
• Evidence-based Treatment 33%
• Atherosclerosis Progression 33%
• Leukotriene B4 (LTB4) 33%
• Conventional Therapy 33%
• Cardiovascular Events 33%
• Phase II Trial 33%
• Antioxidant 33%
• Cardiovascular Morbidity 33%
• Area Cover 33%
• Large Trials 33%
• CCR2 33%
• Recurrent Cardiovascular Events 33%
• Phospholipase A2 Inhibitor 33%
• Incremental Improvement 33%
• Cholesterol-lowering 33%
• Darapladib 33%
• Plaque Vulnerability 33%
• P-selectin 33%
• Cardiovascular Drugs 33%
• Surrogate Endpoint 33%
• Canakinumab 33%
• Selectin Inhibitors 33%
• Soluble Biomarkers 33%
• IL-1 Inhibitors 33%
• Drug Approval 33%
• LDL-cholesterol Lowering 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Atherosclerosis 100%
• Antiinflammatory Agent 100%
• Inflammation 50%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 50%
• Methotrexate 50%
• Cardiovascular Disease 50%
• Biological Marker 25%
• Clinical Trial 25%
• Antiinflammatory Activity 25%
• Antioxidant 25%
• Low Density Lipoprotein Cholesterol 25%
• Phospholipase A2 Inhibitor 25%
• Darapladib 25%
• Cardiovascular Agent 25%
• Canakinumab 25%
• Selectin Antagonist 25%
• Drug Approval 25%